• News

  PHARMO’s annual report

  PHARMO’s annual report Each year we develop our annual report to inform the healthcare providers that contribute to the PHARMO Database Network about the research and developments at the PHARMO Institute. The full report is available (in Dutch) he...

  PHARMO Magazine

  Please find below our newest PHARMO Magazine. In our online magazine you can read more about, amongst other things,  our newest additions to the team, our collaboration with Germany and Italy on biologicals in colorectal cancer, data protection by S...

  PHARMO Magazine

  We are proud to offer you the first edition of our new and improved PHARMO Magazine. In this online magazine you can read about our research, our collaborations with universities and other research institutions and upcoming events. Through our st...

• Events

• Vacancy

  (Senior) Business development manager

  (Senior) Business Development Manager (locatie Utrecht) Wil je bijdragen aan meer transparantie in de gezondheidszorg? Heb je affiniteit met onderzoek? Heb je internationale commerciële ervaring en een internationaal netwerk in de zorg? Dan ben jij...

• 

  What we do

  As an independent research organisation dedicated to the study of epidemiology, drug utilisation, drug safety, health outcomes, and utilisation of healthcare resources PHARMO assists its clients in their decision-making.

  Read more
• 

  What we have

  PHARMO Database Network: we have rapid access to our rich population-based network of databases. Data are derived from different primary and secondary healthcare settings. For our observational studies disease-specific cohorts are created from the various databases.

  Read more

Publications

• Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands

  Read more

• No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study

  Read more

• Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetes

  Read more

• The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression

  Read more